Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Gergely

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Haematologica|March 10, 2022
Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuriaJun-Ichi Nishimura, Kiyoshi Ando, Masayoshi Masuko, et al.
Cell Reports. Medicine|May 17, 2023
Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapyStuart Hawtin, Cédric André, Géraldine Collignon-Zipfel, et al.
The Lancet. Rheumatology|January 24, 2024
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept studyBenjamin A Fisher, Antonia Szanto, Wan-Fai Ng, et al.
Annals of the Rheumatic Diseases|June 17, 2025
Primary Sjögren's Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren's Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI)Simon J Bowman, Raphaele Seror, Raphael Porcher, et al.
Arthritis Research & Therapy|July 23, 2025
Prevalence and outcomes of a pilot definition of severe refractory systemic lupus erythematosus: observations from a multinational Asia-Pacific cohortRangi Kandane-Rathnayake, Worawit Louthrenoo, C S Lau, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Haematologica|March 10, 2022
Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuriaJun-Ichi Nishimura, Kiyoshi Ando, Masayoshi Masuko, et al.
Cell Reports. Medicine|May 17, 2023
Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapyStuart Hawtin, Cédric André, Géraldine Collignon-Zipfel, et al.
The Lancet. Rheumatology|January 24, 2024
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept studyBenjamin A Fisher, Antonia Szanto, Wan-Fai Ng, et al.
Annals of the Rheumatic Diseases|June 17, 2025
Primary Sjögren's Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren's Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI)Simon J Bowman, Raphaele Seror, Raphael Porcher, et al.
Arthritis Research & Therapy|July 23, 2025
Prevalence and outcomes of a pilot definition of severe refractory systemic lupus erythematosus: observations from a multinational Asia-Pacific cohortRangi Kandane-Rathnayake, Worawit Louthrenoo, C S Lau, et al.
Pageof 4